Supplementary data for “Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: lessons for COVID-19 from a nationwide cohort study” by Tomlinson, Laurie et al.
LSHTM Research Online
Tomlinson, Laurie; Iwagami, Masao; Bidulka, Patrick; Wong, Yun Sum; (2020) Supplementary
data for “Comparisons of Staphylococcus aureus infection and other outcomes between users of
angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: lessons for COVID-
19 from a nationwide cohort study”. London School of Hygiene & Tropical Medicine. DOI:
https://doi.org/10.17037/PUBS.04656578 (Unpublished)
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4656578/
DOI: https://doi.org/10.17037/PUBS.04656578
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
  
 
 
Supplementary data for “Comparisons of Staphylococcus aureus infection 
and other outcomes between users of angiotensin-converting-enzyme 
inhibitors and angiotensin II receptor blockers: lessons for COVID-19 from a 
nationwide cohort study” 
  
Supplementary Figure 1. Diagram of study design with definition of exposure periods 
 
ACEI = angiotensin-converting-enzyme inhibitor, ARB = angiotensin II receptor antagonist, CPRD = Clinical Practice Research 
Datalink, HES = Hospital Episode Statistics. 
  
Supplementary Table 1. Characteristics of the 487,165 study participants during follow-up 
 Cohort during time exposed 
to ACEI treatment (PY) 
 (% of 1,759,917 PY) 
Cohort during time exposed  
to ARB treatment (PY) 
 (% of 644,953 PY) 
Age category (years):   
 <55 397,374 (22.6) 112,096 (17.4) 
 55-64 445,516 (25.3) 155,579 (24.1) 
 65-74 463,304 (26.3) 186,896 (29.0) 
 75-84 350,245 (19.9) 151,067 (23.4) 
 ≥85 103,478 (5.9) 39,317 (6.1) 
Sex:   
 Men 972,606 (55.3) 278,890 (43.2) 
 Women 787,312 (44.7) 366,063 (56.8) 
Year:   
 1997-2001 157,853 (9.0) 34,096 (5.3) 
 2002-2006 593,273 (33.7) 213,373 (33.1) 
 2007-2011 734,484 (41.7) 280,502 (43.5) 
 2012-2016 274,307 (15.6) 116,982 (18.1) 
Hypertension 1,387,684 (78.8) 560,727 (86.9) 
Diabetes 432,414 (24.6) 138,224 (21.4) 
Myocardial infarction 197,100 (11.2) 47,323 (7.3) 
Heart failure 117,119 (6.7) 34,701 (5.4) 
Proteinuria diagnosis 56,933 (3.2) 21,382 (3.3) 
Kidney function:   
 Not measured 88,491 (5.0) 23,392 (3.6) 
eGFR ≥60 mL/min/1.73m2 1,292,122 (73.4) 454,076 (70.4) 
eGFR 45-59 mL/min/1.73m2 254,536 (14.5) 109,623 (17.0) 
eGFR 30-44 mL/min/1.73m2 101,337 (5.8) 45,439 (7.0) 
eGFR <30 mL/min/1.73m2 20,652 (1.2) 10,566 (1.6) 
On renal replacement therapy 2,778 (0.2) 1,856 (0.3) 
ACEI = angiotensin-converting-enzyme inhibitor, ARB = angiotensin II receptor antagonist, eGFR = 
estimated glomerular filtration rate, PY = person years.
Supplementary Table 2. Crude rates and adjusted hazard ratio for the incidence of Staphylococcus aureus infections comparing periods prescribed 
angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers 
 Period with ACEI prescription Period with ARB prescription 
Adjusted HR 
(ACEI vs ARB)  
(95% CI)  
No. of 
outcomes 
Follow-up 
length (PY) 
Crude rate  
(/1000 PY)  
(95% CI) 
No. of 
outcomes 
Follow-up 
length (PY) 
Crude rate  
(/1000 PY)  
(95% CI) 
Main analysis:* 3,430 1,759,917 1.95 (1.88-2.02) 1,007 644,953 1.56 (1.47-1.66) 1.18 (1.10-1.27) 
Sensitivity analyses:        
Exposure: Inclusion of time prescribed ACEI and ARB combined 
into time prescribed ACEI 
3,518 1,795,479 1.96 (1.90-2.03) 1,007 644,953 1.56 (1.47-1.66) 1.19 (1.10-1.27) 
Exposure: Grace period between prescriptions: 90 days 3,562 1,784,330 2.00 (1.93-2.06) 1,039 645,531 1.61 (1.51-1.71) 1.18 (1.10-1.26) 
Exposure: Grace period between prescriptions: 30 days 3,202 1,710,676 1.87 (1.8-.94) 943  635,923 1.48 (1.39-1.58) 1.19 (1.11-1.28) 
Covariates: Exclusion of patients with missing kidney function 2,409 134,4731 1.79 (1.72-1.86) 715 485,115 1.47 (1.37-1.59) 1.17 (1.08-1.28) 
Covariates: Adjustment for additional potential confounders ** 3,430 1,759, 917 1.95 (1.88-2.02) 1,007 644,953 1.56 (1.47-1.66) 1.20 (1.12-1.29) 
Outcome: Restriction to S. aureus infection recorded in the 1st 
HES episode 
1,718 1,759,917 0.98 (0.93-1.02) 494 644,953 0.77 (0.70-0.84) 1.17 (1.06-1.30) 
Outcome: Any Staphylococcus infection  
(ICD-10 code A41.0, B95.6, A41.0, G00.3, J15.2, or M00.0) 
4,046 1,758,742 2.30 (2.23-2.37) 1,183 644,484 1.84 (1.73-1.94) 1.16 (1.09-1.24) 
Outcome: Sepsis due to S. aureus  
(ICD-10 code A41.0) 
390 1,766,015 0.22 (0.20-0.24) 122 647,258 0.19 (0.16-0.23) 1.09 (0.89-1.35) 
ACEI = angiotensin-converting-enzyme inhibitor, ARB = angiotensin II receptor antagonist, CI = confidence interval, ICD-10 = International Statistical Classification of Diseases 10th revision, PY 
= person-years. 
*In the main analysis, outcome was defined as hospitalisation with ICD-10 code A41.0 (“Sepsis due to Staphylococcus aureus”) or ICD-10 code B95.6 (“Staphylococcus aureus as the cause of 
diseases classified to other chapters”) at any code position at any episode during hospitalisation, periods with ACEI prescription only and ARB prescription only were compared (ie. period with 
both ACEI and ARB was excluded from the analysis), drug grace period was assumed to be 60 days, and adjusted covariates were age (<55, 55-64, 65-74, 75-84, and ≥85 years), sex, year 
(1997-2001, 2002-2006, 2007-2011, 2012-2016), kidney function (in which period without serum creatinine measurement was grouped into period with eGFR ≥60 mL/min/1.73m2), diagnoses 
of hypertension, diabetes, myocardial infarction, heart failure, and proteinuria (all covariates were time-updated). 
**Additionally adjusted for diagnoses of cancer, rheumatoid arthritis, systematic lupus erythematosus, inflammatory bowel disease, chronic liver disease, chronic pulmonary disease, human 
immunodeficiency virus infection and acquired immune deficiency syndrome, prescription of other antihypertensives (beta blockers, calcium channel blockers, and diuretics), statins, and oral 
corticosteroids, and life-style factors (smoking status, alcohol status, and body mass index). The presence or absence of each diagnosis (anytime from the CPRD registration) and prescription 
(in the past year) was judged at cohort entry and not time-updated. Information on life-style factors was based on that recorded at the closest time point to the cohort entry and not time-
updated.   
Supplementary Table 3. Crude rates and adjusted hazard ratio for the incidence of Staphylococcus aureus infection, comparing periods prescribed 
angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers, stratified by calendar period and smoking status 
 Period with ACEI prescription Period with ARB prescription 
Adjusted HR 
(ACEI vs. ARB) 
(95% CI)  
No. of 
outcomes 
Follow-up 
length (PY) 
Crude rate  
(/1000 PY) (95% CI) 
No. of 
outcomes 
Follow-up 
length (PY) 
Crude rate  
(/1000 PY) (95% CI) 
Subgroup analysis* by year:        
1997-2001 342 157,853 2.17 (1.95 – 2.41) 59 34,096 1.73 (1.34 – 2.23) 0.94 (0.71 – 1.24) 
2002-2006 1,208 593,273 2.04 (1.92 – 2.15) 329 213,373 1.54 (1.38 – 1.72) 1.17 (1.04 – 1.33) 
2007-2011 1,315 734,484 1.79 (1.70 – 1.89) 412 280,502 1.47 (1.33 – 1.62) 1.22 (1.09 – 1.37) 
2012-2016 565 274,307 2.06 (1.90 – 2.24) 207 116,982 1.77 (1.54 – 2.03) 1.18 (1.00 – 1.39) 
Subgroup analysis* by smoking status:**        
Never smoker 1,365 798,401 1.71 (1.62 – 1.80) 448 330,618 1.36 (1.24 – 1.49) 1.22 (1.10 – 1.36) 
Ex-smoker 924 489,112 1.89 (1.77 – 2.02) 284 169,205 1.68 (1.49 – 1.89) 1.09 (0.95 – 1.25) 
Current smoker 954 459,422 2.08 (1.95 – 2.21) 251 142,379 1.76 (1.56 – 2.00) 1.16 (1.01 – 1.34) 
ACEI = angiotensin-converting-enzyme inhibitor, ARB = angiotensin II receptor antagonist, CI = confidence interval, PY = person-year. 
*In the same way as the main analysis (except for adjustment of year for the subgroup analysis by year): outcome was defined as hospitalisation with ICD-10 code A41.0 
(“Sepsis due to Staphylococcus aureus”) or ICD-10 code B95.6 (“Staphylococcus aureus as the cause of diseases classified to other chapters”) at any code position at any 
episode during hospitalisation, periods with ACEI prescription only and ARB prescription only were compared, drug grace period was assumed to be 60 days, and adjusted 
covariates were age (<55, 55-64, 65-74, 75-84, and ≥85), sex, year (1997-2001, 2002-2006, 2007-2011, 2012-2016), kidney function (in which period without serum 
creatinine measurement was grouped into period with eGFR ≥60 mL/min/1.73m2), diagnoses of hypertension, diabetes, myocardial infarction, heart failure, and 
proteinuria (all covariates were time-updated). 
** Information on smoking status was based on that recorded at the closest time point to the cohort entry (either before or after the cohort entry) and not time-updated, 
and patients with missing information on smoking status (n = 6,704) were excluded. 
 
